Geron Announces Ten Imetelstat Presentations at Upcoming American Society of Hematology Annual Meeting - Seite 3

Poster Presentation Details
Abstract: #1283
Date: Saturday, December 5, 2020
Time: 7:00 a.m. – 3:30 p.m. PT

Abstract Title: Imetelstat Treatment Results in Clinical Benefits, Including Improved Overall Survival, in Patients with Higher-Risk Triple Negative Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitors (JAKi)

Poster Presentation Details
Abstract: #3084
Date: Monday, December 7, 2020
Time: 7:00 a.m. – 3:30 p.m. PT

Abstract Title: Treatment with Imetelstat Improves Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in Patients with Relapsed or Refractory Higher-Risk Myelofibrosis

Poster Presentation Details
Abstract: #3088
Date: Monday, December 7, 2020
Time: 7:00 a.m. – 3:30 p.m. PT

Myeloproliferative Neoplasms (MPN) –Poster Presentation

Collaborators at UC San Diego report non-clinical data on hTERT and ADAR1 activity in pre-leukemia stem cells and leukemia stem cells (LSC). In various lab experiments and animal models, treatment with imetelstat can prevent pre-leukemia stem cells from evolving into LSCs, suggesting telomerase inhibition may be an effective strategy for preventing MPN progression.

Abstract Title: Imetelstat Inhibits Telomerase and Prevents Propagation of ADAR1-Activated Myeloproliferative Neoplasm and Leukemia Stem Cells

Poster Presentation Details
Abstract: #1264
Date: Saturday, December 5, 2020
Time: 7:00 a.m. – 3:30 p.m. PT

Two Trials in Progress Poster Presentations – Planned Phase 3 in Refractory MF and Ongoing IMerge Phase 3

Abstracts for this category describe innovative clinical trials that have not reached their primary endpoint to provide opportunities for early engagement and collaboration amongst investigators, translational research, clinical and industry investigators, statisticians and regulators.

Abstract Title: A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor

Poster Presentation Details
Abstract: #2194
Date: Sunday, December 6, 2020
Time: 7:00 a.m. – 3:00 p.m. PT

Abstract Title: IMerge: A Phase 3 Study to Evaluate Imetelstat in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment